Key points are not available for this paper at this time.
Design
Editorial, randomized, open-label
Follow-up
12-week
Epoprostenol in secondary PH and simplified dosing remain investigational; leaves open need for confirmatory trials before practice change.
Continuous infusion of epoprostenol (prostacyclin) is effective in primary pulmonary hypertension, but its efficacy in secondary pulmonary hypertension (which is more common) is unknown. In addition, if its administration could be simplified, the morbidity associated with chronic intravenous infusion might be avoided. Two new studies address these issues. The first was a 12-week randomized, open-label, manufacturer-sponsored, …
No takes yet. Share an insight, caveat, or question.
Richard Saitz (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: